Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Vicapsys Life Sciences, Inc. (VICP)
Cumming, GA, US
Vicapsys Life Sciences, Inc. is primarily focused on bringing its exclusive VICAPSYN product to market, guiding it through development and commercialization. This product's intended application is within the field of transplantation, specifically for various transplant therapies and associated stem-cell uses. Additionally, the company is advancing the development of VYBRIN, a compound based on CXCL12. VYBRIN is being investigated for multiple purposes: preventing the formation of post-surgical adhesions following abdominal operations, coating implantable medical devices and other implants to inhibit fibrosis, and promoting wound healing, with a particular emphasis on diabetic ulcers. The firm, originally incorporated in 1997, transitioned its name from Phage Therapeutics International, Inc. to Vicapsys Life Sciences, Inc. in September 2017. Its operations are headquartered in Suwanee, Georgia.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | -2.67% | -2.67% | -2.67% | -17.51% | +484.00% | +426.13% | +192.00% | -99.96% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+32.3% ★ Q1'25: +50.0% (vs Q1'24)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'25: +27.8% (vs Q1'24)
-
Share dilution Biotechnology: -3.4%+3.0% ★ Q1'25: +10.3% (vs Q1'24)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.96× Q1'25: -0.84× (vs Q1'24)
Owner Earnings
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Seddon, ###-##-#### | 17.72M | 50.34% | 17.72M | — | 17.72M | 10.00 | IN | Florida | 2009-12-10 | ↗ |
| 2 | BARCLAYS GLOBAL INVESTORS, NA. | 888.9K | 2.48% | 4.12M | — | 4.12M | — | BK | United States | 2010-05-20 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2020-04-20 | Wildcat Capital Management, LLC | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 6,070,588 | I | ↗ |
| 2010-09-03 | YURKOWSKI MICHAEL | Director | S-Sale | D | SSGI | 5,000 | 0.15 | 750.00 | 760,000 | — | ↗ |
| 2010-08-09 | YURKOWSKI MICHAEL | Director | S-Sale | D | Common Stock | 20,000 | 0.20 | 4.0K | 765,000 | — | ↗ |
| 2010-05-13 | MOORE BOBBY M JR | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 4,124,622 | — | ↗ |
| 2010-01-26 | YURKOWSKI MICHAEL | Director | A-Award | D | SSGI | 5,000 | 0.60 | 3.0K | 785,000 | — | ↗ |
| 2010-01-14 | YURKOWSKI MICHAEL | Director | S-Sale | D | Common Stock | 5,000 | 0.50 | 2.5K | 790,000 | — | ↗ |
| 2009-12-08 | YURKOWSKI MICHAEL | Director | — | D | Common Stock | 0 | 0.00 | — | 795,000 | — | ↗ |
| 2009-12-08 | SEDDON RYAN | Director / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 17,215,000 | — | ↗ |
| 2009-12-08 | PIER FEDERICO | Director | — | D | Common Stock | 0 | 0.00 | — | 225,000 | — | ↗ |
| 2009-12-08 | GRAMMEN ROBERT | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 1,000,200 | — | ↗ |
| 2009-12-08 | Esping William P. | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 1,466,666 | — | ↗ |
| 2009-11-18 | REES RODGER | Officer | — | D | Warrants | 50,000 | 0.25 | 12.5K | 0 | — | ↗ |
| 2009-06-30 | SEDDON RYAN | Director / 10% Owner | — | D | Warrants | 500,000 | 0.63 | 315.0K | 0 | — | ↗ |
| 2009-06-18 | GRAMMEN ROBERT | 10% Owner | — | D | Warrants | 62,920 | 0.30 | 18.9K | 0 | — | ↗ |
| 2009-04-27 | YURKOWSKI MICHAEL | Director | — | D | Warrants | 50,000 | 0.25 | 12.5K | 0 | — | ↗ |
| 2009-04-27 | Esping William P. | 10% Owner | — | D | Warrants | 315,594 | 0.30 | 94.7K | 0 | — | ↗ |
| 2009-04-01 | YURKOWSKI MICHAEL | Director | — | D | Warrants | 12,000 | 0.68 | 8.2K | 0 | — | ↗ |
| 2009-04-01 | FELDMESSER MARK | Director | — | D | Warrants | 12,000 | 0.68 | 8.2K | 0 | — | ↗ |
| 2008-06-18 | Esping William P. | 10% Owner | — | D | Warrants | 666,667 | 0.95 | 633.3K | 0 | — | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Federico Pier | Chief Executive Officer, Executive Chairman & Interim President | 250.0K | male |
| Jeffery Wright | Chief Financial Officer | 90.0K | male |
| Mark C. Poznansky | Chief Scientist Advisor & Founder | — | — |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for VICP
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
